Posts by: Charles Moore

Charles Moore

Charles Moore has a long-proven track record in both print and digital journalism, touching on a wide range of subjects, from biotech and healthcare to politics and technology. He contributes substantial feature articles research and development for the news site, particularly pertaining to technology.

December 1, 2016December 1, 2016

Nymox Reports Positive New Results from Phase 3 Studies of Possible BPH Treatment

News

Nymox Pharmaceutical Corporation announced new, prospective and randomized results from Phase 3 clinical trial with its lead drug candidate NX-1207 (fexapotide triflutate) for the treatment of benign prostate enlargement (BPH). Findings confirming ... Read more

July 25, 2016July 25, 2016

Duodart, a Fixed-Dose Combo Therapy for BPH, Found Most Cost Effective in Nigerian Study

News

A cost-effectiveness analysis of treatments for moderate to severe benign prostatic hyperplasia (BPH) in Nigeria, done from perspective of the social health service provider, favored the fixed-dose combination of dutasteride and tamsulosin therapy over dutasteride monotherapy. ... Read more

February 29, 2016February 29, 2016

Generic Line of Drugs for BPH Are Advancing, BioPharmcor and VMS Rehab Announce

News

VMS Rehab Systems.Inc., recently reported on the status of its generic drug treatment development program for male health disorders at its majority-owned Amsterdam, Netherlands-based pharmaceutical firm, BioPharmcor BV. BioPharmcor is ... Read more

December 4, 2015December 4, 2015

Options to BPH Surgery Growing, and Showing Promise

News

For decades, the definitive surgical treatment for prostate gland enlargement, or benign prostatic hyperplasia (BPH), has been a procedure called transurethral resection of the prostate (TURP), in which the inside ... Read more

November 24, 2015November 24, 2015

Prostate Treatment Less Invasive, More Precise With Aid of Robotics

News

The Magellan Robotic System, an advanced technology that enables precise steering of guide wires and proprietary robotic catheters through complex anatomy during minimally invasive, endovascular procedures, is designed to offer ... Read more

October 26, 2015October 27, 2015

Prostate Cancer Treatment Using Focused Ultrasound System Gets FDA Approval

News

The U.S. Food and Drug Administration (FDA) has approved SonaCare Medical’s Sonablate 450 focused ultrasound system for ablation therapy on prostate tissue. A pioneer in high intensity focused ultrasound (HIFU) ... Read more

October 13, 2015

Teva Announces Launch of Generic Avodart Capsules For BPH in the U.S.

News

Jerusalem based Teva Pharmaceutical Industries Ltd., has announced the U.S. launch of generic equivalents to GlaxoSmithKline’s Avodart (dutasteride) capsules, 0.5 mgs. Dutasteride is a medication used to treat symptoms of ... Read more

September 21, 2015September 21, 2015

Breckenridge Receives Tentative Approval For Generic Version Of Dutasteride BPH Drug

News

Pharmaceutical marketing, research and development company Breckenridge Pharmaceutical, Inc. announced it has received tentative Abbreviated New Drug Application (ANDA) approval of its generic Dutasteride Soft Gelatin Capsules 0.5mg product. Dutasteride is ... Read more

September 18, 2015September 18, 2015

UCLA Researchers Measure Real Cost Of Care For Common Prostate Condition BPH

News

How much does health care really cost? Earlier this year a team of University of California at Los Angeles (UCLA) Health Sciences researchers using time-driven activity-based costing analysis, for the ... Read more